#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pituitary-dependent Cushing's syndrome Antithrombin III deficiency Cardiac sarcoidosis Hyperoxaluria Cerebral arteriovenous malformation haemorrhagic Angiosarcoma Familial hypertriglyceridaemia Infertility female Diffuse large B-cell lymphoma refractory Retinitis pigmentosa Arrhythmia Facioscapulohumeral muscular dystrophy Retinopathy of prematurity Breast angiosarcoma metastatic Dermatitis More trials…

    Learn about Rare Diseases

    Biotinidase deficiency – Treatment Waldenstrom’s macroglobulinaemia refractory – Treatment Atypical teratoid/rhabdoid tumour of CNS – Diagnostics Atypical haemolytic uraemic syndrome – Trials in Disease Small intestine leiomyosarcoma – Treatment Mitochondrial myopathy Haemophilia A without inhibitors – Life with Disease Hypereosinophilic syndrome – Trials in Disease Von Willebrand’s disease – Trials in Disease Skin angiosarcoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Disodium Folinate VORMATRIGINE Aon-D21 Plerixafor Utreloxastat ZIMISLECEL Bms-986449-03 Sunitinib Rbd1016 Mk-2060 Resmetirom Interferon Alfa Oxybuprocaine Citalopram Hydrobromide Lolium Perenne Mps-102 Ecubectedin Faricimab Ecoo16 Sodium Butyrate More therapies…

    Learn about Your Condition

    Oesophageal carcinoma Hepatic neoplasm Lung cancer metastatic Atrial septal defect Dermatitis Renal cancer metastatic Morning sickness C3 glomerulopathy Delayed graft function Basal cell naevus syndrome Nodular melanoma Diabetic foot infection Contusion Breast cancer male Childhood asthma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Study on Reducing JAK Inhibitor Doses in Patients with Low Disease Activity in Rheumatoid Arthritis Using Tofacitinib and Drug Combination

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Filgotinib
    • Baricitinib
    • Tofacitinib
    France

  • Long-term Safety Study of Exagamglogene Autotemcel for Patients with Sickle Cell Disease or Transfusion-Dependent Thalassemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Sickle cell anaemia
    • Thalassaemia
    Investigated Drugs:
    • Exagamglogene Autotemcel
    Belgium Germany Italy

  • Study to Compare Non-Radioactive Methods for Measuring Kidney Function in Patients with Chronic Kidney Disease Using Sodium Iotalamate, Sodium Iodohippurate, and Iohexol

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal failure
    • Chronic kidney disease
    Investigated Drugs:
    • Sodium Iotalamate (125I)
    • Clemastine
    • Iohexol
    The Netherlands

  • Study on Long-term Safety of Nivolumab and Drug Combination for Cancer Patients from Previous BMS Trials

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Disodium Folinate
    • Ipilimumab
    • Regorafenib
    Austria Belgium Czechia France Germany Greece +4

  • Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Trastuzumab
    • Tucatinib
    • Bevacizumab
    Austria Belgium France Germany Greece Hungary +8

  • Study of Talazoparib and Enzalutamide combination treatment for patients with metastatic prostate cancer who previously received Abiraterone

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Talazoparib
    • Enzalutamide
    France Spain
Previous Page
1 … 496 497 498 499 500 … 1,653
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!